Project Grant R44AI143012

This K23 career development award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports Dr. Lao-Tzu Allan-Blitz's research to develop and pilot a low-cost, point-of-care (POC) CRISPR-based assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settings. The total funding is $195,480 over the 5-year award period from August 2024 to July...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,170 to Latde Diagnostics Corp., a woman-owned small business, to demonstrate the feasibility of a rapid, equitable antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal is to develop a lateral flow assay (LFA) that can detect bacterial growth and determine antibiotic susceptibility...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Sherlock Biosciences, Inc. a $298,948 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a power-free molecular diagnostic device for detecting Chlamydia trachomatis and Neisseria gonorrhoeae, the pathogens that cause the majority of sexually transmitted infections (STIs). The project aims to create an accurate, transportable, and easy-to-use at-home test that does not require...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $163,698 to Magic Lifescience, Inc. to develop a novel point-of-care (POC) molecular diagnostic assay for syphilis detection. The goal is to create a multiplexed genital ulcer disease (GUD) panel test that can rapidly and accurately diagnose syphilis, as well as other pathogens causing GUD, using giant magnetoresistive...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop rapid, point-of-care testing capabilities for detecting antibiotic resistance in Treponema pallidum, the causative agent of syphilis. Specifically, the project aims to develop two complementary approaches: 1) an allele-specific loop-mediated isothermal amplification (AS-LAMP) assay for a...

This $466,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid and ultrasensitive aptamer-based detection technologies for the diagnosis of Treponema pallidum infections, the causative agent of syphilis. The project seeks to address the limitations of current syphilis diagnostic methods by developing aptamers that can specifically and sensitively detect T....

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,483,048 to develop a new point-of-care nucleic acid amplification test (NAAT) for the rapid, pangenomic diagnosis of hepatitis C virus (HCV) in outpatient clinics. The proposed diagnostic test aims to address limitations of current HCV testing protocols by enabling decentralized, clinic-based NAAT...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $312,817 to Giner Inc., a small business R&D firm based in Massachusetts, to develop a point-of-care testing (POCT) instrument for highly sensitive and near-real-time measurement of oxytocin levels. The Phase I program will focus on improving and validating the company's novel electrochemical assay...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The goal is to create a microfluidic-enabled technology that can isolate small numbers of bacteria directly from whole blood, identify bacterial pathogens, and evaluate their antibiotic response within 75...